Drug intelligence / Profile preview

HD1916

Development stage: Phase 3
Lead developer: CSPC ZhongQi Pharmaceutical Technology
Modality: Peptides
Administration: Subcutaneous

Overview

HD1916 is a semaglutide biosimilar being developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, for the treatment of obesity. As a glucagon-like peptide-1 (GLP-1) receptor agonist, it mimics the action of the endogenous GLP-1 hormone to regulate appetite and caloric intake. The drug is a biologic peptide administered via once-weekly subcutaneous injection. It is currently in Phase III clinical development (NCT06604624), where its efficacy and safety are being compared to the originator semaglutide in non-diabetic adults with a BMI of 28 kg/m² or greater.

Other names: semaglutide injection (HD1916)

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on HD1916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD1916.

Explore the full profile